Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
ZUG, Switzerland, March 2, 2016 -- Auris Medical Holding AG (Nasdaq: EARS) today announced that it will release its financial results for the fourth quarter and full year 2015, on Monday, March 14, 2016. Following the announcement, Auris Medical's management will host a live conference call and webcast at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time) to discuss Auris Medical's financial results for the fourth quarter and full year 2015 and provide a general business update.
Auris Medical further announced that it will hold its Annual General Meeting on April 8, 2016. Shareholders registered in the share ledger maintained by our transfer agent, American Stock Transfer & Trust Company, LLC, on April 4, 2016 are entitled to participate in and vote at the Annual General Meeting. Meeting materials will be mailed on or around March 14, 2016. The record date for "street name" holders is March 10, 2016. "Street name" holders should follow the instructions provided by their bank, broker or nominee to vote their shares.
Conference Call / Webcast Information
The call is scheduled for March 14, 2016 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time). To participate in this conference call, dial 1877 280 2296 (USA) or +1 646 254 3388 (International), and enter passcode 8927407. A live, listen-only audio webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at: www.aurismedical.com. A replay will be available approximately two hours following the live call also on the Company's website.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Company: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, [email protected]
Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, [email protected]
HUG#1990658
